EYENOVIA INC

NASDAQ: EYEN (Eyenovia, Inc.)

Last update: 12 Sep, 11:53PM

0.542

-0.02 (-3.71%)

Previous Close 0.563
Open 0.545
Volume 761,455
Avg. Volume (3M) 1,748,679
Market Cap 41,692,588
Price / Sales 808.47
Price / Book 36.17
52 Weeks Range
0.370 (-31%) — 2.57 (374%)
Earnings Date 11 Nov 2024 - 15 Nov 2024
Operating Margin (TTM) -51,661.19%
Diluted EPS (TTM) -0.780
Total Debt/Equity (MRQ) 915.08%
Current Ratio (MRQ) 0.460
Operating Cash Flow (TTM) -30.23 M
Levered Free Cash Flow (TTM) -18.18 M
Return on Assets (TTM) -92.94%
Return on Equity (TTM) -914.66%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Mixed
Biotechnology (Global) Mixed Mixed
Stock Eyenovia, Inc. Mixed Mixed

Stockmoo Score

1.5
Analyst Consensus 2.5
Insider Activity NA
Price Volatility 0.5
Technical Moving Averages 2.5
Technical Oscillators 0.5
Average 1.50

Similar Stocks

Stock Market Cap DY P/E P/B
EYEN 42 M - - 36.17
JAZZ 7 B - 18.72 1.84
ARWR 2 B - - 7.54
SPRY 1 B - - 6.86
VIR 1 B - - 1.02
PHAT 1 B - - -

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 10.00%
% Held by Institutions 13.69%

Ownership

Name Date Shares Held
Lasry Marc 30 Jun 2024 547,807
52 Weeks Range
0.370 (-31%) — 2.57 (374%)
Median 12.00 (2,113.61%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 13 Aug 2024 12.00 (2,113.61%) Buy 0.798

No data within this time range.

Date Type Details
07 Nov 2024 Announcement Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
23 Oct 2024 Announcement Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
16 Oct 2024 Announcement Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
01 Oct 2024 Announcement Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
27 Sep 2024 Announcement Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
26 Sep 2024 Announcement Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
09 Sep 2024 Announcement Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
05 Sep 2024 Announcement Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.
03 Sep 2024 Announcement Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer
23 Aug 2024 Announcement Eyenovia Announces Closing of Public Offering
21 Aug 2024 Announcement Eyenovia Announces Pricing of $5.14 Million Public Offering
20 Aug 2024 Announcement Eyenovia, Inc. Announces Proposed Public Offering
13 Aug 2024 Announcement Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
12 Aug 2024 Announcement Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria